0.5%timolol eye drop monotherapy as a first-line treatment for capillary hemangioma

Abstract

Purpose

To evaluate efficacy and safety of 0.5% Timolol eye drop monotherapy as a first-line treatment for capillary hemangioma

Methods

Retrospective, consecutive, clinical case series

Results

The medical records, including consequent photographs of children with capillary hemangioma treated consecutively with 0.5% timolol solution from October 1^st, 2017 to July 31th, 2018 were reviewed.

11 cases of capillary hemangioma, age 0-8 months, were treated with 0.5% tiomolol eye drop apply to the lesions twice a day monotherapy for at least one month. General physical examination, including vital signs, respiration, skin lesions, eye examination before treatment, and every follow-up visit were done.

8 of 11 cases had shown improvement in size, thickness, and coloration of the lesions without any complications. The clinical improved within 2 months. One case had relapsed after treatment cessation and get better after re-treatment. One case lost follow up. One case failed the monotherapy and needed additive treatment with propranolol and vinblastine.

Conclusion

0.5% Timolol eye drop monotherapy can be used safely as a first-line treatment for capillary hemangima, especially uncomplicated cases.

Key words (5)

Capillary hemangioma, 0.5% Timolol eye drop, Monotherapy, First-line treatment, Efficacy